169 related articles for article (PubMed ID: 29136299)
21. Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease.
Bhutani G; Astor BC; Mandelbrot DA; Mankowski-Gettle L; Ziemlewicz T; Wells SA; Frater-Rubsam L; Horner V; Boyer C; Laffin J; Djamali A
Kidney360; 2021 Feb; 2(2):312-324. PubMed ID: 35373032
[TBL] [Abstract][Full Text] [Related]
22. Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.
Størset E; Åsberg A; Hartmann A; Reisaeter AV; Holdaas H; Skauby M; Bergan S; Midtvedt K
Nephrology (Carlton); 2016 Oct; 21(10):821-7. PubMed ID: 26854648
[TBL] [Abstract][Full Text] [Related]
23. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
[TBL] [Abstract][Full Text] [Related]
24. [Metabolic disorders in renal transplant recipients].
Mikolasević I; Jelić I; Sladoje-Martinović B; Orlić L; Zivcić-Cosić S; Vuksanović-Mikulicić S; Mijić M; Racki S
Acta Med Croatica; 2012 Jul; 66(3):235-41. PubMed ID: 23441539
[TBL] [Abstract][Full Text] [Related]
25. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
Santos AH; Casey MJ; Xuerong W; Womer KL
Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
[TBL] [Abstract][Full Text] [Related]
26. Risk and outcome of pyelonephritis among renal transplant recipients.
Graversen ME; Dalgaard LS; Jensen-Fangel S; Jespersen B; Østergaard L; Søgaard OS
BMC Infect Dis; 2016 Jun; 16():264. PubMed ID: 27287058
[TBL] [Abstract][Full Text] [Related]
27. Postrenal transplant malignancy: Incidence, risk factors, and prognosis.
Elserwy NA; Lotfy EE; Fouda MA; Mahmoud MI; Donia AF; Mashaly ME; Abbas MH; Abuelmagd MM; Abouelenein RK; Ismail MI; Bakr MA
Saudi J Kidney Dis Transpl; 2017; 28(3):579-588. PubMed ID: 28540896
[TBL] [Abstract][Full Text] [Related]
28. Malignancy after renal transplantation in the new era of immunosuppression.
Watorek E; Boratynska M; Smolska D; Patrzalek D; Klinger M
Ann Transplant; 2011; 16(2):14-8. PubMed ID: 21716180
[TBL] [Abstract][Full Text] [Related]
29. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
30. Recurrent and de novo glomerulonephritis following renal transplantation: higher rates of rejection and lower graft survival.
Mirioglu S; Caliskan Y; Goksoy Y; Gulcicek S; Ozluk Y; Sarihan I; Seyahi N; Kilicaslan I; Turkmen A; Sever MS
Int Urol Nephrol; 2017 Dec; 49(12):2265-2272. PubMed ID: 29039058
[TBL] [Abstract][Full Text] [Related]
31. De Novo Visceral Malignancies in Renal Transplant Recipients: A Single Center Experience of 2054 Recipients for More Than 30 Years.
Zavos G; Moris D; Kostakis ID; Vernadakis S; Bokos J; Zavvos V; Lionaki S; Boletis J
Exp Clin Transplant; 2015 Aug; 13(4):313-8. PubMed ID: 26295181
[TBL] [Abstract][Full Text] [Related]
32. Outcomes Associated with Steroid Avoidance and Alemtuzumab among Kidney Transplant Recipients.
Serrano OK; Friedmann P; Ahsanuddin S; Millan C; Ben-Yaacov A; Kayler LK
Clin J Am Soc Nephrol; 2015 Nov; 10(11):2030-8. PubMed ID: 26342042
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
34. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
[TBL] [Abstract][Full Text] [Related]
35. Kidney Transplantation Rates Across Glomerulonephritis Subtypes in the United States.
OʼShaughnessy MM; Liu S; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Transplantation; 2017 Oct; 101(10):2636-2647. PubMed ID: 28207635
[TBL] [Abstract][Full Text] [Related]
36. Ischemic heart disease after renal transplantation in patients on cyclosporine in Spain.
Marcén R; Morales JM; Arias M; Fernández-Juárez G; Fernández-Fresnedo G; Andrés A; Rodrigo E; Pascual J; Domínguez B; Ortuño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S286-90. PubMed ID: 17130276
[TBL] [Abstract][Full Text] [Related]
37. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
38. Polycystic kidney disease and cancer after renal transplantation.
Wetmore JB; Calvet JP; Yu AS; Lynch CF; Wang CJ; Kasiske BL; Engels EA
J Am Soc Nephrol; 2014 Oct; 25(10):2335-41. PubMed ID: 24854270
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of the renal outcome of pediatric lupus nephritis.
Wang LC; Yang YH; Lu MY; Chiang BL
Clin Rheumatol; 2004 Aug; 23(4):318-23. PubMed ID: 15293092
[TBL] [Abstract][Full Text] [Related]
40. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.
Koyawala N; Silber JH; Rosenbaum PR; Wang W; Hill AS; Reiter JG; Niknam BA; Even-Shoshan O; Bloom RD; Sawinski D; Nazarian S; Trofe-Clark J; Lim MA; Schold JD; Reese PP
J Am Soc Nephrol; 2017 Jul; 28(7):2188-2200. PubMed ID: 28320767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
